{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:13:54Z","timestamp":1793211234267,"version":"4.5.0"},"reference-count":101,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,2,14]],"date-time":"2014-02-14T00:00:00Z","timestamp":1392336000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:p>Cancer\u2010related anemia (CRA) is due to multiple etiologies, including chemotherapy\u2010induced myelosuppression, blood loss, functional iron deficiency, erythropoietin deficiency due to renal disease, marrow involvement with tumor as well as other factors. The most common treatment options for CRA include iron therapy, erythropoietic\u2010stimulating agents (ESAs), and red cell transfusion. Safety concerns as well as restrictions and reimbursement issues surrounding ESA therapy for CRA have resulted in suboptimal treatment. Similarly, many clinicians are not familiar or comfortable using intravenous iron products to treat functional iron deficiency associated with CRA. This article summarizes our approach to treating CRA and discusses commonly encountered clinical scenarios for which current clinical guidelines do not apply. Am. J. Hematol. 89:203\u2013212, 2014. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23628","type":"journal-article","created":{"date-parts":[[2013,11,11]],"date-time":"2013-11-11T04:32:45Z","timestamp":1384144365000},"page":"203-212","source":"Crossref","is-referenced-by-count":197,"title":["Diagnosis and treatment of cancer\u2010related anemia"],"prefix":"10.1002","volume":"89","author":[{"given":"Jeffrey A.","family":"Gilreath","sequence":"first","affiliation":[{"name":"Department of Pharmacy Huntsman Cancer Institute University of Utah Hospitals and Clinics Salt Lake City Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Stenehjem","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Huntsman Cancer Institute University of Utah Hospitals and Clinics Salt Lake City Utah"},{"name":"Department of Pharmacotherapy Pharmacotherapy Outcomes Research Center, College of Pharmacy, University of Utah Salt Lake City Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Rodgers","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Utah Hospitals and Clinics Salt Lake City Utah"},{"name":"Department of Pathology University of Utah Hospitals and Clinics Salt Lake City Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,14]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj189"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.6004\/jnccn.2012.0044","article-title":"A perspective on the evolution of management of cancer\u2010 and chemotherapy\u2010induced anemia","volume":"10","author":"Rodgers GM","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1835"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.7643"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21837"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.2201"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2012.0064"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2008.00524.x"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.06.008"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.37"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.19.1616"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(98)00024-3"},{"key":"e_1_2_12_14_1","first-page":"275","article-title":"The biology of pure red cell aplasia","volume":"28","author":"Dessypris EN","year":"1991","journal-title":"Semin Hematol"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06295.x"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06648.x"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1983.00301.x-i1"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.04080"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2004.11.005"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M307182200"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0024"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.9.2786.009k30_2786_2792"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1078\/0344-0338-00362"},{"key":"e_1_2_12_24_1","first-page":"1009","article-title":"Malignant histiocytosis. A phenotypic and genotypic investigation","volume":"136","author":"Cattoretti G","year":"1990","journal-title":"Am J Pathol"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20783"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc5054"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.12.008"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.06.019"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2008.0044"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1191"},{"key":"e_1_2_12_31_1","volume-title":"Epogen (epoetin alfa) [Prescribing Information]","year":"2012"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.12.1289"},{"key":"e_1_2_12_33_1","volume-title":"ARANESP (darbepoetin alfa) [Prescribing Information]","year":"2012"},{"key":"e_1_2_12_34_1","volume-title":"INFeD\u00ae (iron dextran injection) [Prescribing Information]","year":"2009"},{"key":"e_1_2_12_35_1","volume-title":"Ferrlecit\u00ae (sodium ferric gluconate complex in sucrose injection) [Prescribing Information]","year":"2011"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409808102"},{"key":"e_1_2_12_37_1","volume-title":"INJECTAFER (ferric carboxymaltose injection) [Prescribing Information]","year":"2013"},{"key":"e_1_2_12_38_1","volume-title":"Cyanocobalamin Injection, USP [Prescribing Information]","year":"2006"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/86.3.718"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1548-5315(11)70057-2"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.113.059683"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1159\/000045437"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.42"},{"key":"e_1_2_12_44_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1512.1512","article-title":"Current practice in diagnosis and treatment of chemotherapy\u2010induced anemia in five european countries\u2014A patient record study","volume":"116","author":"Beguin Y","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.3644"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-2-231"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404562"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21779"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.4620"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2051"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.119"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90530-9"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.56.2.6"},{"key":"e_1_2_12_54_1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.6004\/jnccn.2012.0066","article-title":"Total dose iron dextran infusion in cancer patients: Is it SaFe2+?","volume":"10","author":"Gilreath JA","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.femsim.2004.11.010"},{"key":"e_1_2_12_56_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1525-139X.2004.17115.x","article-title":"Intravenous iron and the risk of infection in end\u2010stage renal disease patients","volume":"17","author":"Brewster UC","year":"2004","journal-title":"Semin Dial"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f4822"},{"key":"e_1_2_12_58_1","unstructured":"Cancer\u2010and Chemotherapy\u2010Induced Anemia v2.2014. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Available atwww.nccn.org."},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008030255"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh185"},{"key":"e_1_2_12_61_1","first-page":"566","article-title":"Clinical use of the total dose intravenous infusion of iron dextran","volume":"111","author":"Auerbach M","year":"1988","journal-title":"J Lab Clin Med"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds338"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfi253"},{"key":"e_1_2_12_64_1","volume-title":"Venofer\u00ae (iron sucrose injection) [Prescribing Information]","year":"2011"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21154"},{"key":"e_1_2_12_66_1","first-page":"319","article-title":"Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor","volume":"61","author":"Alvarez\u2010Hern\u00e1ndez X","year":"1989","journal-title":"Lab Invest"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2459"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041809"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199006143222401"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-286260"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPBAY9KRZF8NUC"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2008.04.009"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1126\/stke.3062005re12"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-427765"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21090"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12311"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-4-199408150-00009"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.21.2377"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-S3-12"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.02072.x"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01734.x"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390902"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb03692.x"},{"key":"e_1_2_12_84_1","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1182\/blood.V76.9.1718.1718","article-title":"Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers","volume":"76","author":"McMahon FG","year":"1990","journal-title":"Blood"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh899"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0101"},{"key":"e_1_2_12_87_1","article-title":"Treatment patterns among cancer patients with anemia who do not respond to erythropoietin\u2010stimulating agents","author":"Girvan AC","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_88_1","first-page":"CD003407","article-title":"Erythropoietin or darbepoetin for patients with cancer","volume":"12","author":"Tonia T","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.02.003"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2013-0104"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.16.1211"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.9.2983.009k27_2983_2989"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e32833cf1d6"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12328"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.01.029"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23552"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.2.442"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.13-S3-11"},{"key":"e_1_2_12_99_1","first-page":"272e","article-title":"Prevalence of chronic kidney disease in anemic oncology patients","volume":"29","author":"Diaz AH","year":"2009","journal-title":"Pharmacotherapy"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.2885"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907845"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cml008"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23628","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T06:07:11Z","timestamp":1716098831000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1002\/ajh.23628"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23628","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}